For this, prospective studies in children are necessary and essential to address critical aspects, including histiocytosis pathophysiology, the sufficiency of vemurafenib as a standalone treatment in cases with BRAF mutations, timing of initiation, dose ideal, duration and the consideration of targeted therapy as a chronic treatment option. The gene discussed is BRAF; the disease is Histiocytosis.